BR112021026899A2 - Compostos heterocíclicos - Google Patents

Compostos heterocíclicos

Info

Publication number
BR112021026899A2
BR112021026899A2 BR112021026899A BR112021026899A BR112021026899A2 BR 112021026899 A2 BR112021026899 A2 BR 112021026899A2 BR 112021026899 A BR112021026899 A BR 112021026899A BR 112021026899 A BR112021026899 A BR 112021026899A BR 112021026899 A2 BR112021026899 A2 BR 112021026899A2
Authority
BR
Brazil
Prior art keywords
compounds
heterocyclic compounds
heterocyclic
processes
making
Prior art date
Application number
BR112021026899A
Other languages
English (en)
Inventor
Benoit Hornsperger
Bernd Kuhn
Carsten Kroll
Fionn O'hara
Flore Reggiani
Hans Richter
Maurice Biedermann
Miroslav Kosar
Uwe Grether
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112021026899A2 publication Critical patent/BR112021026899A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

compostos heterocíclicos. a presente invenção refere-se a novos compostos heterocíclicos possuindo a fórmula geral (i), em que r1, r2, x, e y são como definidos neste documento, composições incluindo os compostos, processos de fabricação dos compostos e métodos de uso dos compostos.
BR112021026899A 2019-07-09 2020-07-07 Compostos heterocíclicos BR112021026899A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19185088 2019-07-09
PCT/EP2020/069074 WO2021005034A1 (en) 2019-07-09 2020-07-07 New heterocyclic compounds

Publications (1)

Publication Number Publication Date
BR112021026899A2 true BR112021026899A2 (pt) 2022-05-10

Family

ID=67220669

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026899A BR112021026899A2 (pt) 2019-07-09 2020-07-07 Compostos heterocíclicos

Country Status (18)

Country Link
US (1) US20220242876A1 (pt)
EP (1) EP3997096A1 (pt)
JP (1) JP2022539604A (pt)
KR (1) KR20220034104A (pt)
CN (1) CN114096545A (pt)
AR (1) AR119376A1 (pt)
AU (1) AU2020311584A1 (pt)
BR (1) BR112021026899A2 (pt)
CA (1) CA3145338A1 (pt)
CL (1) CL2022000019A1 (pt)
CO (1) CO2022000186A2 (pt)
CR (1) CR20220004A (pt)
IL (1) IL288987A (pt)
MX (1) MX2022000243A (pt)
PE (1) PE20220515A1 (pt)
TW (1) TW202116781A (pt)
WO (1) WO2021005034A1 (pt)
ZA (1) ZA202110352B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
EP3837263A1 (en) 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG New heterocyclic compounds as monoacylglycerol lipase inhibitors
EP4028403B1 (en) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014110401A (ru) * 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
EP2934533B1 (en) * 2012-12-19 2017-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US10323038B2 (en) * 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
BR112019014099A2 (pt) * 2017-01-23 2020-02-11 Pfizer Inc. Compostos espiro-heterocíclico como inibidores de magl
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Also Published As

Publication number Publication date
CR20220004A (es) 2022-01-31
CN114096545A (zh) 2022-02-25
JP2022539604A (ja) 2022-09-12
AU2020311584A1 (en) 2022-01-20
MX2022000243A (es) 2022-02-03
EP3997096A1 (en) 2022-05-18
KR20220034104A (ko) 2022-03-17
PE20220515A1 (es) 2022-04-07
IL288987A (en) 2022-02-01
TW202116781A (zh) 2021-05-01
AR119376A1 (es) 2021-12-15
CO2022000186A2 (es) 2022-01-17
US20220242876A1 (en) 2022-08-04
WO2021005034A1 (en) 2021-01-14
ZA202110352B (en) 2022-08-31
CL2022000019A1 (es) 2022-10-21
CA3145338A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
CO2021002382A2 (es) Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
BR112019006571A2 (pt) derivados de éter de isoxazolila como gaba a alfa5 pam
BR112021026899A2 (pt) Compostos heterocíclicos
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
CL2020002423A1 (es) Nuevos compuestos heterocíclicos
BR112015022804A2 (pt) novos derivados de octahidro-pirrol [3,4-c]-pirrol e seus análogos como inibidores de autotaxina
BR112018006080A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
BR112018006034A2 (pt) compostos bicíclicos como inibidores de atx
BR112022003982A2 (pt) Compostos heterocíclicos
BR112015004111A2 (pt) novos derivados bicíclicos
BR112014010644A2 (pt) novos derivados de aril-quinolina
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
BR112017026682A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
CO2022002000A2 (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
BR112022002375A2 (pt) Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl
UY36473A (es) Composiciones con efecto inhibidor de la ureasa mejorado que comprenden triamida del ácido (tio)fosfórico y otros compuestos, tales como aminas y colorantes
BR112022003704A2 (pt) Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
BR112022003357A2 (pt) Compostos heterocíclicos
BR112023003580A2 (pt) Compostos heterocíclicos
BR112015024109A2 (pt) derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp)
BR112022018828A2 (pt) Derivados de benzodiazepina como gaba a gamma1 pams
UY38941A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
BR112023023527A2 (pt) Inibidores de nlrp3